Trial investigates monoclonal antibody for chronic hepatitis D
Bluejay Therapeutics’ AZURE-1 global pivotal clinical trial evaluating brelovitug (BJT-778) for the treatment of chronic hepatitis D (CHD) has dosed its first patient.
Brelovitug is an investigational fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the hepatitis D virus (HDV) and the hepatitis B virus (HBV).
It is designed to neutralise and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles.
“CHD is the most severe form of viral hepatitis with rapid progression to cirrhosis, liver failure and liver cancer. There are currently limited treatment options for CHD, with no therapy approved by the US FDA,” said Nancy Shulman, Chief Medical Officer of Bluejay Therapeutics. “The initiation of our AZURE-1 pivotal clinical trial is a critical step toward addressing the unmet medical needs of people living with CHD. We plan to recruit and complete this trial as rapidly as possible.”
AZURE-1 is evaluating brelovitug as a monotherapy for adults living with CHD compared to delayed treatment.
Phase II data for brelovitug in CHD were presented at The Liver Meeting 2024 of the American Association for the Study of Liver Diseases (AASLD), demonstrating that brelovitug achieved 100% virologic response across all dose arms and up to 78% combined virologic response and ALT normalisation as a monotherapy in participants with CHD.
In January 2025, brelovitug received FDA Breakthrough Therapy designation for the treatment of CHD. It has also received PRIME and Orphan designations from the European Medicines Agency.
CHD is the most severe form of viral hepatitis due to the potential for rapid progression to liver cirrhosis, liver cancer and liver-related death. There are currently no approved treatments for CHD in the US and most countries worldwide.
Diana Spencer, Senior Digital Content Editor, DDW
